A Success Story at a Glance

Within only a few years since its foundation in 2003, CEVEC has established a growing global customer base in the major biopharmaceutical markets.

• 2003: Founded by an internationally renowned group of university professors in the biotech cluster of Cologne, Germany

• 2004: Invention of the CAP® technology by successful immortalization of  human   amniocytes

• 2007: Completion of entire regulatory data sets and development of CAP- T® technology

• 2008: Entrance into European market

• 2010: CEVEC opens subsidiary in the USA and enters the Asia / Pacific market

• 2011: Closing of 6M € series B financing round 

• 2012:         o Closing of 2,8M € series C financing round

                     o Several strategic license agreements

                     o Several cell line sales agreements

• 2013:        o Foundation of a spin-out company, CAP-CMV GmbH focusing  exlusively                          on the clinical development of a novel human CMV vaccine.

                     o Completion of first clinical Phase I trial in humans with a CAP® derived                             biotherapeutic.